The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with obesity or type 2 diabetes, compared to placebo, GLP-1 receptor agonists (GLP-1 RAs), and insulin. Method: PubMed, Embase, and the Cochrane Library were searched on 17 January 2024, focusing on phase II and III randomized controlled trials (RCTs). We included studies involving adults with T2D or obesity, comparing tirzepatide to placebo, GLP-1 RAs, or insulin. The primary outcomes were the proportion of participants achieving ≥5%, ≥10%, and ≥15% weight loss targets. Secondary outcomes included changes in body weight, waist circumference, HbA1c levels, and blood pressure. Safety outcomes focused on adverse event rates. Meta-analyses were performed, and risk of bias was assessed using the Cochrane Risk-of-Bias tool version 2. Results: Fourteen RCTs involving 14,713 patients were included. Tirzepatide significantly increased the proportion of participants achieving weight loss targets, and reduced body weight, waist circumference, HbA1c, and blood pressure versus placebo and insulin. Compared with GLP-1 RAs, tirzepatide provided comparable or better outcomes in weight loss, waist circumference, and glycemic control. The incidence of gastrointestinal adverse events was significantly higher at all doses of tirzepatide compared to placebo and insulin. When compared with GLP-1 RAs, higher doses of tirzepatide were associated with increased risk of nausea, diarrhea, and decreased appetite, but not vomiting. Conclusions: Tirzepatide is an effective option for managing weight and improving metabolic outcomes in patients with T2D or obesity. However, it is associated with an increased risk of gastrointestinal adverse events, especially at higher doses. Therefore, close monitoring should be considered in clinical practice. Registration: PROSPERO CRD42021283449.
Overview
CoChat Summary
## TL;DR
This systematic review and meta-analysis of 14 randomized clinical trials (14,713 patients) found that tirzepatide improved weight, glycemic, and some blood-pressure outcomes in adults with type 2 diabetes and/or obesity. Benefits were strongest at higher doses, but adverse events and treatment discontinuation also increased, especially at 15 mg.
## Key findings
- The review included 14 RCTs with 14,713 patients; 11 trials enrolled participants with diabetes and 3 focused on overweight/obesity without diabetes.
- Compared with placebo, tirzepatide increased the proportion achieving at least 5%, 10%, and 15% weight loss; at 15 mg, the odds ratios were 16.82 for 5%, 12.20 for 10%, and 20.25 for 15% weight loss.
- Tirzepatide reduced body weight, waist circumference, and HbA1c versus placebo, GLP-1 RAs, and insulin; for example, vs placebo, body weight SMDs were −1.05 (5 mg), −1.25 (10 mg), and −1.80 (15 mg), and HbA1c SMDs were −1.45, −1.59, and −1.56.
- Safety tradeoff: any adverse events were higher at 5 mg and 15 mg vs placebo (OR 1.54 and 1.53), and treatment discontinuation due to adverse events increased with dose vs placebo (OR 1.76, 2.13, 2.92 for 5/10/15 mg).
## Methods
- Systematic review and meta-analysis registered in PROSPERO (CRD42021283449) and reported per PRISMA.
- Searched PubMed, Embase, and the Cochrane Library on 17 January 2024 for phase II/III randomized controlled trials in adults with type 2 diabetes or obesity/overweight with one health-related condition; comparators were placebo, GLP-1 RAs, or insulin.
- Meta-analyses used R 4.0.3; continuous outcomes were summarized with SMDs and dichotomous outcomes with ORs, with subgroup analyses by comparator and tirzepatide dose (5, 10, 15 mg).
## Limitations
- The paper states that GLP-1 RA doses were generally lower than approved therapeutic doses, which could affect comparative effectiveness.
- The trial durations were relatively short, limiting conclusions about long-term efficacy and safety.
- Many trials comparing tirzepatide with insulin or GLP-1 RAs were open-label, which may have introduced performance and detection bias, especially for subjective adverse-event outcomes.
- All included studies were funded by Eli Lilly, and the authors note it is unclear whether this introduced reporting bias.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 2 Not valid · 1 Not checked · 43 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Recently, several large-scale randomized controlled trials (RCTs) specifically targeting patients with obesity but without diabetes have been published [24,25,26,27,28].”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 1. Introduction
What the sources say
- Supportedcites [24] Aronne, 2024, Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial, JAMA source
The Methods (Study Design and Participants; page not available) describe SURMOUNT-4 as a phase 3 randomized trial at 70 sites that enrolled adults with obesity or overweight and a weight-related complication, while excluding people with diabetes. The Results (Study Participants; page not available) report that 783 participants enrolled and 670 were randomized. This source is one example of the trials identified by the citation cluster; it need not establish the number of other trials. (LLM, conf=0.93)
- Supportedcites [25] Wadden, 2023, Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial, Nat. Med. source
SURMOUNT-3 is one example of the trials identified by the group of citations. The Methods describe a randomized, placebo-controlled trial enrolling adults with obesity or overweight, the exclusion criteria rule out diabetes, and the Results report 579 randomized participants. The paper was published in 2023. (LLM, conf=0.92)
- Disputedcites [26] Garvey, 2023, Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet sourceExperimental — accuracy not yet measured
The Trial design and participants section (page unavailable) says participants were required to have type 2 diabetes. The Participants section reports 938 people were randomized. Although this is a large randomized trial of obesity treatment, it contradicts the cited sentence’s defining qualifier, “without diabetes.” (LLM, conf=0.94)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [27] Gao, 2023, Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: The SURPASS-AP-Combo trial, Nat. Med. source
- Disputedcites [28] Rosenstock, 2023, Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
The Methods identify this as a randomized phase 3b trial, but the Participants section states that eligible adults had type 2 diabetes inadequately controlled with basal insulin. It therefore cannot serve as an example of an RCT specifically targeting patients with obesity but without diabetes. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Some studies have demonstrated that tirzepatide achieves greater weight loss compared to existing GLP-1 RAs [20,21,22].”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 1. Introduction
What the sources say
- Supportedcites [20] Karagiannis, 2022, Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis, Diabetologia source
The Results (Body weight) report that tirzepatide produced larger reductions in body weight than GLP-1 receptor agonists at all three doses studied. The Discussion identifies semaglutide and dulaglutide as the GLP-1 receptor agonist comparators. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [21] Ding, 2024, Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis, Pharmacol. Res. source
- Not checked — no full text of the sourcecites [22] Alkhezi, 2023, Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials, Obes. Rev. source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Tirzepatide has shown significant effects on weight management with the reductions in body weight, body mass index (BMI), and waist circumference (WC) in patients with obesity or diabetes [23].”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 1. Introduction
What the sources say
- Supportedcites [23] Rohani, P., Malekpour Alamdari, N., Bagheri, S.E., Hekmatdoost, A., and Sohouli, M.H. (2023). The effects of subcutaneous Tirzepatide on obesity and overweight: A systematic review and meta-regression analysis of randomized controlled trials. Front. Endocrinol., 14. source
The Abstract’s Conclusions state that tirzepatide significantly reduced body weight, BMI, and waist circumference. The Discussion reports the same overall finding and describes trials involving people with obesity or type 2 diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For diarrhea, both 10 mg and 15 mg tirzepatide were associated with higher risk [OR 1.48 (95% CI 1.07–2.04), I2 = 0%; OR 1.42 (95% CI 1.03–1.96), I2 = 0%].”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 2. Results > 2.7. Safety of Tirzepatide
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences in vomiting rates across all tirzepatide doses compared to GLP-1 RAs.”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 2. Results > 2.7. Safety of Tirzepatide
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
18 more claims
Create a free account to see all 53 claims and every source verdict.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 2. Results > 2.6. Change in DBP
“### 2.6. Change in DBP Tirzepatide demonstrated a statistically significant reduction in SBP, starting from the dose of 5 mg [SMD −0.33 (95% CI −0.57, −0.09), I2 = 70%], 10 mg [SMD −0.29 (95% CI −0.51, −0.07), I2 = 77%], and 15 mg [SMD −0.42 (95% CI −0.54, −0.29), I2 = 55%] relative to placebo (Supplementary Figure S7A).”
§ The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials > 2. Results > 2.6. Change in DBP
“### 2.6. Change in DBP”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“These medications mimic the action of the glucagon-like peptide-1 hormone, which enhances insulin secretion, suppresses glucagon release, and slows gastric emptying, thereby promoting satiety and reducing appetite [14].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
Seravalle, G., & Grassi, G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.013 · Cited by 909
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 2×
“Ultimately, 14 RCTs involving 14,713 patients were included in this meta-analysis (Figure 1) [24–37].”
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Cited by
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
de Paulo, R. S., Bonifácio, D. B., de Carvalho, M. H. L., & Bressan, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70779 · Cited by 12
“This reinforces the notion, also corroborated by systematic reviews, that the profile of gastrointestinal symptoms is largely determined by the pharmacodynamics of the agonists and not by modifiable lifestyle factors [41, 45].”
Yılmaz, N., & Baştemir, M. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s584175 · Cited by 15
“18 Despite the overall consistency in demonstrating the glycemic efficacy of GLP-1 RAs and dual GIP/GLP-1 receptor agonists, substantial heterogeneity exists across studies.”
Caturano, A., Nilo, D., Lorenzo, G. D., Rocco, M. P., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Moretto, S. M., Acierno, C., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43143 · Cited by 9
“Pooled analyses suggest additional cardiovascular benefits through improvements in blood pressure, triglycerides, and inflammatory markers [168,169].”
Talay, L., Hom, J., Scott, T., & Ahuja, N. K. (2025) · Healthcare · doi:10.3390/healthcare14010060 · Cited by 5
“This outcome demonstrates an effectiveness level comparable to the mean weight loss achieved in highly controlled RCTs of Tirzepatide [8], and the 11-month figure reported in the engaged cohort of the Johnson et al. study (M = 21.5%).”
Influential
Metadata
- Authors
- Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C.
- Affiliations
- The Ohio State University (US)
- Shanghai Medical College of Fudan University (CN)
- St. John's University (US)
- Sichuan University (CN)
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2025-04-30
- Volume
- 18
- Issue
- 5
- Pages
- 668
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC12114739
- OpenAlex
- W4410029173
- Semantic Scholar
- 8e42c1df6fd5ee6076ae8ae42e958f07b5c2de9c
- Cited by
- 19
- References
- 50
- Citations by year
- 2026: 13 · 2025: 6
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, type 2 diabetes, obesity, weight loss, GLP-1 receptor agonists, insulin, glycemic control, HbA1c, gastrointestinal adverse effects, drug safety, body weight, waist circumference, blood pressure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://app.cochat.ai/papers/10.3390/ph18050668
- The paper
- Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025). The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials. Pharmaceuticals. https://doi.org/10.3390/ph18050668
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
